Gene · 4070
Papers3,230
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
321 to 340 of 3,230
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Management of adverse events associated with TROP2-targeted antibody-drug conjugates in cancer patients. | Crit Rev Oncol Hematol | 2026 | 41587589 | PubTator, text mining | PubMed |
| Synthetic zipper mediated pre-targeting system for near-infrared photoimmunotherapy. | iScience | 2026 | 41585490 | PubTator, text mining | PubMed |
| Global advances and future directions in lung cancer care: expert consensus and strategic priorities. | ESMO Open | 2026 | 41579430 | PubTator, text mining | PubMed |
| Recent advances in bispecific antibody-drug conjugates for breast cancer therapy. | Cancer Chemother Pharmacol | 2026 | 41579215 | PubTator, text mining | PubMed |
| Effectiveness of sacituzumab govitecan in metastatic triple-negative breast cancer: a real-world retrospective cohort study from Central Europe. | Oncologist | 2026 | 41578063 | PubTator, text mining | PubMed |
| Expression of antibody drug conjugate target antigens in ovarian sex cord stromal Tumors. | Gynecol Oncol | 2026 | 41576550 | PubTator, text mining | PubMed |
| Major clinical advances in gynecologic cancer in 2025: from de-escalation strategies to precision therapies beyond BRCA. | J Gynecol Oncol | 2026 | 41575332 | PubTator, text mining | PubMed |
| Trop2-Targeted [18F]AlF-RESCA-RT4 ImmunoPET/CT in Guiding Clinical Surgeries of Thyroid Cancers: A Proof-of-Concept Study. | Mol Pharm | 2026 | 41575262 | PubTator, text mining | PubMed |
| Complete Pathological Response to Neoadjuvant Cisplatin, Etoposide, and Pembrolizumab in Small Cell Breast Carcinoma: A Case Report and Review of the Literature. | Case Rep Oncol | 2026 | 41567956 | PubTator, text mining | PubMed |
| Diagnostic Performance of a Multiantigen Print ImmunoAssay (MAPIA) for Antibody Detection in Human Neurocysticercosis. | Open Forum Infect Dis | 2026 | 41567266 | PubTator, text mining | PubMed |
| Updates on Antibody Drug Conjugates and Bispecific T-Cell Engagers in SCLC. | Antibodies (Basel) | 2026 | 41562777 | PubTator, text mining | PubMed |
| Bispecific and multispecific T-cell engagers: advancing the future of immunotherapy. | Antib Ther | 2026 | 41561192 | PubTator, text mining | PubMed |
| Potential Targets and Biomarkers of Radionuclide Therapy in Breast Cancer. | Cancer Innov | 2026 | 41555955 | PubTator, text mining | PubMed |
| Expanding the payload scope in antibody-drug conjugates by delivery of hydroxy-containing drugs through self-immolative phosphoramidates. | Nat Commun | 2026 | 41554755 | PubTator, text mining | PubMed |
| The development of a next generation NK cell engager platform by integrating a potency-reduced IL-15 variant to enhance antitumor activity. | Antib Ther | 2026 | 41550975 | PubTator, text mining | PubMed |
| Cataract surgery with autosomal recessive cornea plana caused by a novel KERA mutation. | Am J Ophthalmol Case Rep | 2026 | 41550454 | PubTator, text mining | PubMed |
| The making of multispecific immunoglobulins - a clinical perspective. | MAbs | 2026 | 41542910 | PubTator, text mining | PubMed |
| Molecular decoupling of lineage identity and morphology in aggressive variant prostate cancer. | medRxiv | 2026 | 41542660 | PubTator, text mining | PubMed |
| Optimum Serum Concentration Enhances Migration of MDA-MB-231 Triple-Negative Breast Cancer Cells and Promotes Intracellular Delivery of Proapoptotic Domain via Cell-Penetrating Peptides. | Mol Pharm | 2026 | 41539681 | PubTator, text mining | PubMed |
| Computational frameworks for enhanced extracellular vesicle biomarker discovery. | Exp Mol Med | 2026 | 41535547 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4070/papers?page=17